CJC-1295 with DAC vs without DAC: what the difference actually means

The peptide most researchers know as CJC-1295 began its life in the labs of ConjuChem, a Montreal biotechnology company that spent the early 2000s working on a specific problem in peptide pharmacology. The problem was half-life: peptide hormones, when injected, are cleared from circulation within minutes by kidney filtration and enzymatic degradation, which makes them impractical as therapeutics for any condition requiring sustained exposure. ConjuChem’s solution was a technology they called DAC, short for Drug Affinity Complex, which attaches a reactive chemical group to the peptide that forms a covalent bond with circulating albumin after injection. Albumin, the most abundant protein in human blood, has a half-life of roughly 19 days, so anything that binds to it gets a free ride through the circulatory system instead of being rapidly cleared. This single chemical modification was the difference between a peptide that required multiple daily injections and one that could be administered once per week, and it is the entire reason the DAC versus no-DAC distinction exists in the first place.

I · The molecule underneath the modification

Before the DAC group enters the conversation, it is worth understanding what the peptide itself is, because the four amino acid substitutions in the sequence tell a story about the engineering decisions ConjuChem made. Endogenous growth hormone releasing hormone, or GHRH, is a 44-amino acid peptide produced in the hypothalamus that travels to the anterior pituitary and binds to the GHRH receptor, triggering the release of growth hormone. The problem with native GHRH is that it has an extremely short half-life of roughly 7 minutes in circulation, which limits its therapeutic value to diagnostic settings where a single pulse of GH is the goal.²

ConjuChem’s research team, led by Dr. Jean-Claude Tardif and collaborators in Montreal, made four targeted substitutions to the GHRH sequence to create what they called tetra-substituted GHRH(1-29). First, they replaced the alanine at position 2 with D-alanine, which blocks the enzyme dipeptidyl peptidase-4 from cleaving the first two amino acids and inactivating the peptide within minutes. Second, they substituted glutamine at position 8 with its D-isomer to reduce oxidation. Third, they replaced asparagine at position 15 with lysine, and fourth, they replaced asparagine at position 29 with lysine, both of which improved receptor binding affinity and added additional resistance to proteolytic degradation. The result was a peptide that, even without DAC conjugation, has a half-life of roughly 30 minutes instead of 7, which is enough time for the pituitary to register a signal and release a pulse of growth hormone before the peptide is cleared.³

The name "CJC-1295 without DAC" is, in practice, used interchangeably with Modified GRF 1-29 or Mod GRF(1-29), and these terms all refer to the same tetra-substituted peptide without the Drug Affinity Complex attached. When researchers and clinicians say "CJC-1295" without qualification, they usually mean the DAC-conjugated version, which is why the "no DAC" distinction matters so much in practice. The two compounds share a peptide backbone but produce radically different pharmacokinetic profiles, which makes them different tools for different purposes rather than interchangeable versions of the same thing.

II · What the DAC group actually does

The DAC mechanism is deceptively simple in concept but has profound consequences for how the peptide behaves in the body. After subcutaneous injection, the maleimide group on the CJC-1295 molecule seeks out the free cysteine-34 residue on circulating albumin, which happens to be one of the few exposed thiol groups in human plasma. When the maleimide encounters this cysteine, it undergoes a Michael addition reaction that locks the peptide to the albumin molecule permanently, at least until the albumin itself is degraded and recycled by the body’s normal protein turnover machinery.⁴

Because the peptide stays bound to albumin and circulates continuously, the pituitary gland is exposed to a persistent GHRH-receptor signal rather than the brief, sharp pulse that occurs with the non-DAC form. This persistence changes the quality of the GH release entirely: instead of a single, transient surge of GH that mimics the body’s natural pulsatile secretion pattern, the DAC version produces what researchers describe as a "GH bleed," a continuous, low-grade elevation of growth hormone that persists for days. The distinction between a pulse and a bleed is not a minor detail of drug design. It is the central physiological question that determines whether CJC-1295 with DAC is useful at all.

III · The pharmacokinetic split: pulse versus bleed

The pituitary gland does not release growth hormone in a steady trickle. It releases it in pulses, and this pulsatility is not an accident of anatomy. It is a functional requirement of the GH/IGF-1 axis. Each pulse of GH travels to the liver and other tissues, where it stimulates the production of insulin-like growth factor 1, which then feeds back to the hypothalamus and pituitary to suppress further GH release until the IGF-1 signal fades, at which point the next pulse fires. This negative feedback loop creates the oscillatory pattern that defines normal GH physiology, and disrupting it has consequences that extend well beyond the simple question of how much GH is in the blood at any given moment.⁶

“"Growth hormone secretion in humans is pulsatile, with secretory bursts accounting for more than 85% of daily GH production. Between pulses, serum GH concentrations fall to undetectable levels, creating an intermittent rather than continuous pattern of tissue exposure." [cite: Veldhuis and Bowers, Endocrine Reviews, 2003]” [cite: @@CITE@@]

CJC-1295 without DAC, upon injection, reaches the pituitary within minutes, triggers a single GH pulse, and is cleared before it can produce a second pulse. The result is a pharmacokinetic profile that resembles the body’s own secretory pattern: a sharp rise in GH followed by a return to baseline over roughly 90 to 120 minutes. This is why the non-DAC form is almost always paired with a growth hormone releasing peptide such as ipamorelin, which amplifies the pulse by suppressing somatostatin tone at the same moment the GHRH analog is stimulating the pituitary.⁷

CJC-1295 with DAC, once injected, binds to albumin and remains in circulation for days, continuously signaling the GHRH receptor throughout that period. The pituitary responds by releasing GH, but because the signal never turns off, the normal pulsatile rhythm is replaced by a sustained elevation of GH that gradually declines as the albumin-bound peptide is cleared. This "GH bleed" pattern raises GH and IGF-1 to levels that are persistently above baseline, which is a fundamentally different physiological state from a brief, natural pulse.

IV · What each pharmacokinetic profile means in practice

The pulsatile-versus-bleed distinction is not merely an academic curiosity about pharmacokinetic curves. It has practical implications that researchers and clinicians weigh when deciding which form to use. The pulsatile pattern, because it allows the GH receptor to reset between pulses, avoids the phenomenon of tachyphylaxis, in which continuous stimulation causes the receptor population on target cells to decrease. This downregulation is a well-characterized phenomenon across many hormone systems: if a receptor is constantly activated, the cell responds by removing receptors from its surface to restore homeostasis, which means that more ligand is required over time to achieve the same effect.⁸

In the context of GH, continuous exposure to GHRH has been shown in animal models to reduce pituitary responsiveness over days to weeks. A study by Jetté and colleagues at ConjuChem, published in Endocrinology in 2005, demonstrated that CJC-1295 with DAC produced sustained GH and IGF-1 elevations in rats for several days after a single injection, but also noted that the magnitude of the GH response diminished with repeated dosing, consistent with the tachyphylaxis that would be predicted from continuous receptor stimulation.⁹

The practical consequence of these differences is that CJC-1295 with DAC has largely been abandoned by many researchers in favor of the non-DAC form, not because the DAC version does not work, but because the pulsatile approach is physiologically more plausible as a long-term strategy. The non-DAC version, typically administered in the evening to coincide with the body’s natural GH surge during sleep, produces a single pulse that the pituitary can respond to repeatedly without the receptor fatigue that continuous stimulation produces. This makes it a tool for supporting the body’s existing GH rhythm rather than overriding it.

V · Why the pulse-versus-bleed distinction matters for pairing decisions

The GHRH receptor and the ghrelin receptor, which is the target of growth hormone releasing peptides like ipamorelin, sit on the same somatotroph cells in the anterior pituitary, and they converge on the same intracellular signaling cascade that triggers GH release. When both receptors are activated simultaneously, the GH pulse is larger than the sum of what each agonist would produce alone, because the two signals converge on phospholipase C and adenylate cyclase pathways that amplify each other’s effects.¹⁰

“"Co-administration of a GHRH analog and a GHRP produces a synergistic GH response that exceeds the arithmetic sum of the individual responses, confirming that these two receptor classes operate through complementary but convergent intracellular mechanisms." [cite: Bowers et al., Journal of Clinical Endocrinology and Metabolism, 1990]” [cite: @@CITE@@]

This synergy is the reason the non-DAC form of CJC-1295 is almost never used alone. The standard research protocol pairs CJC-1295 without DAC with ipamorelin because ipamorelin is the most selective commercially available GHRP, producing minimal off-target effects on prolactin and cortisol, while still delivering the somatostatin suppression and direct ghrelin-receptor activation that amplify the GHRH signal. The result is a GH pulse that is larger than the body’s natural pulse but retains the same temporal pattern: a sharp rise, a brief plateau, and a return to baseline within roughly 2 hours.¹¹

The DAC version, by contrast, does not pair well with GHRPs because the pharmacokinetics do not align. A GHRP produces a brief pulse that lasts roughly 2 hours, while CJC-1295 with DAC produces a continuous signal that lasts for days. Pairing a short-acting GHRP with a long-acting GHRH analog does not produce the amplified pulse that co-administration of two short-acting peptides achieves, because the GHRP signal has faded long before the DAC-conjugated peptide stops signaling. This mismatch makes the DAC version a standalone compound by default, which is part of why many researchers have moved away from it: the amplified pulse from a GHRH analog plus a GHRP is a more powerful and physiologically coherent intervention than a continuous GHRH signal alone.

VI · The research landscape and what remains unknown

ConjuChem advanced CJC-1295 with DAC through Phase I safety studies in healthy volunteers and into a Phase II trial in patients with growth hormone deficiency, but the program was discontinued for business reasons, not safety concerns. The company pivoted toward a different pipeline candidate, and the CJC-1295 program was shelved before larger, longer-duration trials could establish the kind of safety and efficacy data that the research community would need to draw firm conclusions about chronic use.¹²

The non-DAC version of CJC-1295, under the name Modified GRF 1-29, has seen more widespread use in research settings, particularly in combination with ipamorelin, because its pharmacokinetic profile is well understood and the pulsatile pattern it produces is consistent with established GH physiology. It has become a staple compound in the research community for studying GH axis stimulation in the context of body composition and recovery.

The research community does not yet know whether the theoretical concern about GH receptor desensitization from continuous stimulation actually materializes at clinically meaningful magnitudes in humans, and whether any such desensitization is reversible upon discontinuation. The animal data suggest that tachyphylaxis occurs, but the magnitude and time course in humans have not been studied systematically. Similarly, the question of whether the larger and more sustained IGF-1 elevation from the DAC version produces meaningfully different tissue-level effects compared to the pulsatile approach has not been answered in controlled human trials.

The takeaway for researchers and clinicians reviewing the evidence is that CJC-1295 without DAC and CJC-1295 with DAC are not two versions of the same intervention. They are two different interventions that share a peptide backbone but produce fundamentally different physiological signals. The non-DAC form produces a brief, natural pulse that can be amplified by co-administration with a GHRP. The DAC form produces a sustained elevation that raises IGF-1 further but at the cost of disrupting the body’s pulsatile GH rhythm. The choice between them depends on whether the goal is to support the existing GH axis or to override it, and the published evidence to date suggests that supporting the existing axis is the more physiologically coherent strategy for most research applications.